1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
about
Phosphodiesterase 4-targeted treatments for autoimmune diseasesDeletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesisNitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophoreChemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Crystal structure of phosphodiesterase 4D and inhibitor complex(1)Novel therapy for asthma.Systemic therapy of atopic dermatitis.Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitorsCilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.ABCD of the phosphodiesterase family: interaction and differential activity in COPDThe effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.Role of PDE4 in superoxide anion generation through p44/42MAPK regulation: a cAMP and a PKA-independent mechanism.CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activitiesPhosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast.Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation.Treating COPD with PDE 4 inhibitors.Apremilast for the treatment of psoriatic arthritis.Apremilast for the treatment of psoriasis.Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation.Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate.Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.Chiral-Zn(NTf2)2-complex-catalyzed diastereo- and enantioselective direct conjugate addition of arylacetonitriles to alkylidene malonates.Indium Tribromide Catalyzed Coupling Reaction of Enol Ethers with Silyl Ketene Imines toward the Synthesis of β,γ-Unsaturated Nitriles.The therapeutic potential of PDE4 inhibitors.
P2860
Q21245284-0BA59A00-8192-4A78-AE69-5C5720EAE339Q24553313-D0603981-DE05-42EF-9B88-47CDB59B3618Q24569706-AA1C5FDE-5F45-4DEF-A91B-76871BEAC911Q24634179-B91B75EE-DEF1-4C8C-A576-604B0E372A79Q27639850-969EF186-07DE-4622-AEA0-49AD72B20ECEQ34074657-390D60F9-E743-43D3-84B9-3D7EBEE80898Q34106943-2461FB4B-450E-4A62-BA52-97555B0E53FBQ34138086-00507B16-28A1-42CC-AD4D-27586EE363DDQ34481601-3C831600-A213-44CD-999C-DE5CF08881FAQ34961511-0CC5F27A-9DF2-4FBB-A323-039BD08A207CQ35041052-990BF11F-E1D4-411A-BA08-3E1CCF41D1E4Q35047671-F7370882-9F48-4641-A79E-24B38E786A1AQ35048762-86709D8C-A500-4904-8643-78A32D55EDB5Q36677411-D12E52A2-64A0-4788-8B6F-DD92556386BAQ36964706-2A14A6E2-A5AE-4EA0-9A30-5695155891A9Q37082594-173E10C2-D3CB-4DF2-8738-91169E730DADQ38202205-325CB36E-B9E5-4A63-AF31-6475B79C1274Q38561061-E2C778CA-5848-42D8-92C7-EFD011BBE5B5Q39329054-7264D846-5020-46A0-A917-96163A1E1E56Q42002871-56E9D74F-C9A2-4CEE-98E9-4A9C547655EAQ42117582-5676C47B-19CB-45BC-BBD0-0DF637BDE75CQ42496826-15F4B190-B4AB-4EA8-A1F5-7A9EC8D53925Q43061572-B8607399-C3C8-4FC4-9D69-03C2F245B430Q46142907-B372378B-6F20-43F8-8C69-E60713653DC2Q46579810-2D1F6572-56EA-4E91-8CC8-7607B2695C83Q51666388-77E85146-AE96-4F4F-AB2F-1262D0195BD0Q53619316-E6DF9B77-03FA-49E1-95AD-1FFAED4658C3
P2860
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@ast
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@en
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@nl
type
label
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@ast
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@en
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@nl
prefLabel
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@ast
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@en
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@nl
P2093
P356
P1476
1,4-Cyclohexanecarboxylates: p ...... 4 for the treatment of asthma.
@en
P2093
Barnette MS
Bochnowicz S
Christensen SB
Cieslinski LB
DeWolf WE Jr
Eggleston DS
Forster CJ
P304
P356
10.1021/JM970090R
P407
P577
1998-03-01T00:00:00Z